HEALTH SCIENCES ACQUISITIONS CORP 2 HSAQ 深 沪
等待开盘 08-25 09:30:00 美东时间
13.31
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 13.31
- 总市值 14.92万
- 52周最高 13.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9.41
- 委 比 0.00%
- 总股本 1.12万
- 历史最高 14.66
- 量 比 0
- 振 幅 0.00%
- 历史最低 9.41
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Splash Beverage to rename as Endovia Health Sciences; shares up
Splash Beverage (SBEV) will change its corporate name to Endovia Health Sciences and begin trading on NYSE American under ticker EDVA at market open on August 24, 2026. The rebranding marks the Compan...
08-21 21:42
Splash Beverage Group GAAP EPS of -$2.30
Splash Beverage Group press release (SBEV): 1H GAAP EPS of -$2.30. Revenue of $4,224. More on Splash Beverage Group Splash Beverage will officially become Endovia Health Sciences on August 21 Splash B...
08-21 02:45
Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences
Splash Beverage Group reported a 64% year-over-year decline in its loss from continuing operations for the first half of 2026, attributed to cost reduction initiatives as the company transitions from alcoholic beverages to cannabinoid health sciences. Strategic developments include securing a global license for CannEpil®, expanding into veterinary applications, collaborating with Lupvindol Biosciences for FDA-regulated product development, and pr...
08-20 13:00
Splash Beverage will officially become Endovia Health Sciences on August 21
Splash Beverage Group (SBEV) will officially change its corporate name to Endovia Health Sciences on August 2 and start trading under the new ticker symbol of EDVA. The company noted that the name cha...
08-12 23:31
Splash Beverage Group to Rebrand as Endovia Health Sciences
Splash Beverage Group, Inc. will rebrand as Endovia Health Sciences, Inc. on August 21, 2026, with a new ticker symbol "EDVA" and website EndoviaSciences.com. The name change reflects the company's strategic shift from a legacy beverage business to a diversified cannabinoid health sciences platform focused on commercializing pharmaceutical assets, advancing FDA-regulated human and veterinary therapeutics, and developing innovative cannabinoid wel...
08-12 14:03
Hawkins, Inc. to Participate in Seaport Research Partners’ 15th Annual Summer Investor Conference
Hawkins, Inc., a leading water treatment and specialty ingredients company, announced that CEO Patrick Hawkins and CFO Jeff Oldenkamp will participate in Seaport Research Partners’ 15th Annual Summer Investor Conference on August 18-19, 2026. The virtual event is expected to attract over 500 institutional investors. Founded in 1938, Hawkins generates approximately $1.1 billion in annual revenue and operates 66 facilities across 28 states, serving...
08-07 20:05
Noveris Says No Operational Change Behind Surge in Trading Activity
Mydecine Innovations Group ( ($TSE:NVRS) ) has shared an announcement. Noveris ...
08-07 03:02
Hawkins, Inc. Increases its Quarterly Cash Dividend by 5% to $0.20 Per Share
Hawkins, Inc. announced on July 29, 2026, that its Board of Directors increased the quarterly cash dividend by 5% to $0.20 per share, payable on August 28, 2026, to shareholders of record as of August 14, 2026. The company has consistently paid dividends since 1985. Founded in 1938, Hawkins is a leading water treatment and specialty ingredients company with 66 facilities in 28 states, generating approximately $1.1 billion in revenue in fiscal 202...
07-29 20:05
Oracle Corp Stock (ORCL) Closed Down by 4.27% on Jul 24: What Signal Does It Send?
• Oracle shares declined amid sector-wide cloud migration concerns and macroeconomic inflationary pressures. • High capital expenditure for data center scaling creates investor uncertainty regarding long-term returns. • Technical indicators show an oversold condition while market sentiment remains in the bearish zone.
07-24 20:15
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
Sunnybrook’s Odette Cancer Centre in Toronto has joined BriaCell’s pivotal Phase 3 clinical trial for metastatic breast cancer. The trial, which is evaluating Bria-IMT in combination with an immune checkpoint inhibitor, has over 80 active sites across the U.S. and now includes Canada. The study’s primary endpoint is overall survival, with an interim analysis planned. BriaCell recently received a positive recommendation from an independent Data Sa...
07-16 11:30
